{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:42:15Z","timestamp":1792201335166,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11102-026-01769-4","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:15:01Z","timestamp":1792199701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cabergoline for non-functioning pituitary adenomas: an update on an old clinical controversy"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-7965","authenticated-orcid":false,"given":"Omer Denizhan","family":"Tatar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7990-8350","authenticated-orcid":false,"given":"Melia","family":"Karakose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ecl.2025.06.002","volume":"54","author":"U Habib","year":"2025","unstructured":"Habib U, Tritos NA (2025) Clinically nonfunctioning pituitary adenomas. Endocrinol Metab Clin North Am 54:563\u2013585. https:\/\/doi.org\/10.1016\/j.ecl.2025.06.002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1769_CR2","doi-asserted-by":"publisher","first-page":"E533","DOI":"10.1227\/NEU.0000000000001389","volume":"79","author":"JW Lucas","year":"2016","unstructured":"Lucas JW, Bodach ME, Tumialan LM, Oyesiku NM, Patil CG, Litvack Z et al (2016) Congress of neurological surgeons systematic review and evidence-based guideline on primary management of patients with nonfunctioning pituitary adenomas. Neurosurgery 79:E533\u2013E535. https:\/\/doi.org\/10.1227\/NEU.0000000000001389","journal-title":"Neurosurgery"},{"key":"1769_CR3","doi-asserted-by":"publisher","first-page":"E539","DOI":"10.1227\/NEU.0000000000001385","volume":"79","author":"J Sheehan","year":"2016","unstructured":"Sheehan J, Lee CC, Bodach ME, Tumialan LM, Oyesiku NM, Patil CG et al (2016) Congress of neurological surgeons systematic review and evidence-based guideline for the management of patients with residual or recurrent nonfunctioning pituitary adenomas. Neurosurgery 79:E539\u2013E540. https:\/\/doi.org\/10.1227\/NEU.0000000000001385","journal-title":"Neurosurgery"},{"key":"1769_CR4","unstructured":"Drummond JB, Ribeiro-Oliveira A Jr, Soares BS (2022) Non-functioning pituitary adenomas. In: Feingold KR, Adler RA, Ahmed SF (eds) Endotext [Internet]. MDText.com, Inc., South Dartmouth (MA). Updated 12 October 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534880\/. Accessed 27 September 2026"},{"key":"1769_CR5","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1210\/jc.2003-030859","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P et al (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89:1674\u20131683. https:\/\/doi.org\/10.1210\/jc.2003-030859","journal-title":"J Clin Endocrinol Metab"},{"key":"1769_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/cen.12684","volume":"82","author":"L Vieira Neto","year":"2015","unstructured":"Vieira Neto L, Wildemberg LE, Moraes AB, Colli LM, Kasuki L, Marques NV et al (2015) Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clin Endocrinol (Oxf) 82:739\u2013746. https:\/\/doi.org\/10.1111\/cen.12684","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1769_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2265.2005.02295.x","volume":"63","author":"Y Greenman","year":"2005","unstructured":"Greenman Y, Tordjman K, Osher E, Veshchev I, Shenkerman G, Reider-Groswasser II et al (2005) Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf) 63:39\u201344. https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02295.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1769_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1530\/EJE-16-0206","volume":"175","author":"Y Greenman","year":"2016","unstructured":"Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T et al (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 175:63\u201372. https:\/\/doi.org\/10.1530\/EJE-16-0206","journal-title":"Eur J Endocrinol"},{"key":"1769_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/COC.0000000000000505","volume":"42","author":"RL Batista","year":"2019","unstructured":"Batista RL, Musolino NRC, Cescato VAS, da Silva GO, Medeiros RSS, Herkenhoff CGB et al (2019) Cabergoline in the management of residual nonfunctioning pituitary adenoma: a single-center, open-label, 2-year randomized clinical trial. Am J Clin Oncol 42:221\u2013227. https:\/\/doi.org\/10.1097\/COC.0000000000000505","journal-title":"Am J Clin Oncol"},{"key":"1769_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s11102-022-01257-5","volume":"25","author":"MS Botelho","year":"2022","unstructured":"Botelho MS, Franzini IA, Nunes-Nogueira VDS, Boguszewski CL (2022) Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis. Pituitary 25:810\u2013818. https:\/\/doi.org\/10.1007\/s11102-022-01257-5","journal-title":"Pituitary"},{"key":"1769_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11060-022-04149-7","volume":"160","author":"P Iglesias","year":"2022","unstructured":"Iglesias P, Biagetti B, Araujo-Castro M, Alcazar V, Guerrero-Perez F, Rivero N et al (2022) Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma. J Neurooncol 160:351\u2013359. https:\/\/doi.org\/10.1007\/s11060-022-04149-7","journal-title":"J Neurooncol"},{"key":"1769_CR12","doi-asserted-by":"publisher","first-page":"506","DOI":"10.20945\/2359-3997000000495","volume":"66","author":"G Vargas-Ortega","year":"2022","unstructured":"Vargas-Ortega G, Gonzalez-Virla B, Balcazar-Hernandez L, Arreola-Rosales R, Benitez-Rodriguez FJ, Lopez-Felix B et al (2022) Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: a single center clinical experience. Arch Endocrinol Metab 66:506\u2013511. https:\/\/doi.org\/10.20945\/2359-3997000000495","journal-title":"Arch Endocrinol Metab"},{"key":"1769_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-023-01365-w","volume":"27","author":"I Ayalon-Dangur","year":"2024","unstructured":"Ayalon-Dangur I, Turjeman A, Hirsch D, Robenshtok E, Tsvetov G, Gorshtein A et al (2024) Cabergoline treatment for surgery-naive non-functioning pituitary macroadenomas. Pituitary 27:52\u201360. https:\/\/doi.org\/10.1007\/s11102-023-01365-w","journal-title":"Pituitary"},{"key":"1769_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/endocrines7020015","volume":"7","author":"T Tam","year":"2026","unstructured":"Tam T, Soong E, Saada L, Borg A, Dorward N, Swords F et al (2026) Real-world outcomes of cabergoline treatment in non-functioning pituitary adenomas: an insight into dose responsiveness and radiological follow-up at a UK tertiary centre. Endocrines 7:15. https:\/\/doi.org\/10.3390\/endocrines7020015","journal-title":"Endocrines"},{"key":"1769_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12020-025-04473-8","volume":"91","author":"GP Mauro","year":"2026","unstructured":"Mauro GP, Rebello LG, Da R\u00f3z LM, Gico VC, Weltman E, de Souza EC et al (2026) Radiotherapy regimens and concurrent cabergoline use for non-functioning pituitary neuroendocrine tumors: a large, single-center cohort. Endocrine 91:60. https:\/\/doi.org\/10.1007\/s12020-025-04473-8","journal-title":"Endocrine"},{"key":"1769_CR16","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s40618-025-02674-6","volume":"48","author":"B Biagetti","year":"2025","unstructured":"Biagetti B, Cardona-Arias A, Men\u00e9ndez Torre E, Aulinas A, Ruz-Caracuel I, Garc\u00eda Centeno R et al (2025) Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study. J Endocrinol Invest 48:2857\u20132867. https:\/\/doi.org\/10.1007\/s40618-025-02674-6","journal-title":"J Endocrinol Invest"},{"key":"1769_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1055\/a-2096-1340","volume":"55","author":"SD Rikvold","year":"2023","unstructured":"Rikvold SD, Pedersen MB, Andreassen M, Krogh J (2023) Natural history of non-functioning pituitary adenomas: a systematic review and meta-analysis. Horm Metab Res 55:443\u2013451. https:\/\/doi.org\/10.1055\/a-2096-1340","journal-title":"Horm Metab Res"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.eprac.2025.12.007","volume":"32","author":"PU Freda","year":"2026","unstructured":"Freda PU, Bruce JN, Post KD, Jin Z, Kostadinov J, Khandji AG (2026) Prospective observational study of 118 clinically nonfunctioning pituitary adenomas. Endocr Pract 32:548\u2013557. https:\/\/doi.org\/10.1016\/j.eprac.2025.12.007","journal-title":"Endocr Pract"},{"key":"1769_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11102-026-01669-7","volume":"29","author":"A Bavaresco","year":"2026","unstructured":"Bavaresco A, Bovo G, Mondin A, Scaroni C, Voltan G, Mazzeo P et al (2026) Natural history of non-functioning pituitary neuroendocrine tumours: impact of baseline characteristics and gender-specific clinical presentations. Pituitary 29:64. https:\/\/doi.org\/10.1007\/s11102-026-01669-7","journal-title":"Pituitary"},{"key":"1769_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11102-026-01752-z","volume":"29","author":"C Jerning","year":"2026","unstructured":"Jerning C, H\u00f6ybye C, Bensing S, Ed\u00e9n Engstr\u00f6m B, Al-Shamkhi N, Ekman B et al (2026) Natural history of conservatively managed nonfunctioning pituitary macroadenomas in the elderly: a study from the Swedish Pituitary Registry. Pituitary 29:147. https:\/\/doi.org\/10.1007\/s11102-026-01752-z","journal-title":"Pituitary"},{"key":"1769_CR21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10143-024-03126-0","volume":"47","author":"M Castle-Kirszbaum","year":"2024","unstructured":"Castle-Kirszbaum M, McCormack A, Kam J, King J, Wang YY, Goldschlager T (2024) Quality of life in non-functioning pituitary adenoma: a systematic review. Neurosurg Rev 47:867. https:\/\/doi.org\/10.1007\/s10143-024-03126-0","journal-title":"Neurosurg Rev"},{"key":"1769_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11102-011-0316-1","volume":"15","author":"F Gabalec","year":"2012","unstructured":"Gabalec F, Beranek M, Netuka D, Masopust V, Nahlovsky J, Cesak T et al (2012) Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas. Pituitary 15:222\u2013226. https:\/\/doi.org\/10.1007\/s11102-011-0316-1","journal-title":"Pituitary"},{"key":"1769_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/eje.0.1440051","volume":"144","author":"P Petrossians","year":"2001","unstructured":"Petrossians P, Ronci N, Valdes Socin H, Kalife A, Stevenaert A, Bloch B et al (2001) ACTH silent adenoma shrinking under cabergoline. Eur J Endocrinol 144:51\u201357. https:\/\/doi.org\/10.1530\/eje.0.1440051","journal-title":"Eur J Endocrinol"},{"key":"1769_CR24","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/neuonc\/noae130","volume":"26","author":"S Lin","year":"2024","unstructured":"Lin S, Wang L, Han C, Dai Y, Li C, Liu Y et al (2024) Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting G\u03b1q\/PLC\/PKC\u03b3\/STAT3 axis. Neuro Oncol 26:2010\u20132026. https:\/\/doi.org\/10.1093\/neuonc\/noae130","journal-title":"Neuro Oncol"},{"key":"1769_CR25","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.3390\/cancers15123218","volume":"15","author":"G Di Muro","year":"2023","unstructured":"Di Muro G, Mangili F, Esposito E, Barbieri AM, Catalano R, Treppiedi D et al (2023) A \u03b2-arrestin 2-biased dopamine receptor type 2 (DRD2) agonist is more efficacious than cabergoline in reducing cell proliferation in PRL-secreting but not in non-functioning pituitary tumor cells. Cancers (Basel) 15:3218. https:\/\/doi.org\/10.3390\/cancers15123218","journal-title":"Cancers (Basel)"},{"key":"1769_CR26","doi-asserted-by":"publisher","first-page":"R37","DOI":"10.1093\/ejendo\/lvag028","volume":"194","author":"F Mangili","year":"2026","unstructured":"Mangili F, Treppiedi D, Di Muro G, Panseri N, Bosoni L, Peverelli E et al (2026) Biological targets and therapeutic strategies in the treatment of non-functioning pituitary tumors: state-of-the-art. Eur J Endocrinol 194:R37\u2013R48. https:\/\/doi.org\/10.1093\/ejendo\/lvag028","journal-title":"Eur J Endocrinol"},{"key":"1769_CR27","doi-asserted-by":"publisher","first-page":"102917","DOI":"10.1016\/j.arcmed.2023.102917","volume":"54","author":"G Vargas-Ortega","year":"2023","unstructured":"Vargas-Ortega G, Gonzalez-Virla B, Romero-Gameros CA (2023) Pharmacological treatment of non-functioning pituitary adenomas. Arch Med Res 54:102917. https:\/\/doi.org\/10.1016\/j.arcmed.2023.102917","journal-title":"Arch Med Res"},{"key":"1769_CR28","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.3390\/ijms26125898","volume":"26","author":"N Mogar","year":"2025","unstructured":"Mogar N, Zhang D, Heaney AP (2025) A bridge too far? Towards medical therapy for clinically nonfunctioning pituitary tumors. Int J Mol Sci 26:5898. https:\/\/doi.org\/10.3390\/ijms26125898","journal-title":"Int J Mol Sci"},{"key":"1769_CR29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz NR, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 19:722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"key":"1769_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11102-024-01383-2","volume":"27","author":"MH Almalki","year":"2024","unstructured":"Almalki MH, Alsuraikh MA, Almalki E, Aziz F, Almazrouei R, AlDahmani KM et al (2024) Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study. Pituitary 27:197\u2013203. https:\/\/doi.org\/10.1007\/s11102-024-01383-2","journal-title":"Pituitary"},{"key":"1769_CR31","doi-asserted-by":"publisher","first-page":"1869083","DOI":"10.3389\/fendo.2026.1869083","volume":"17","author":"R Bilbao","year":"2026","unstructured":"Bilbao R, Serralunga J, Loschiavo N, Altuna R, Manfre J, Capani F et al (2026) A systematic review and meta-analysis on impulse-control disorders in patients with pituitary adenomas exposed to dopamine agonists. Front Endocrinol (Lausanne) 17:1869083. https:\/\/doi.org\/10.3389\/fendo.2026.1869083","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1769_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11102-026-01728-z","volume":"29","author":"KB Daniel","year":"2026","unstructured":"Daniel KB, Glezer A, de Queiroz NL, Correa-Silva SR, Trentin MBF, Fujiwara MT et al (2026) Increased impulsivity and higher odds of compulsive shopping among cabergoline-treated patients with prolactinoma: a case-control study. Pituitary 29:130. https:\/\/doi.org\/10.1007\/s11102-026-01728-z","journal-title":"Pituitary"},{"key":"1769_CR33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s11154-024-09909-6","volume":"25","author":"AG Ioachimescu","year":"2024","unstructured":"Ioachimescu AG, Kelestimur F (2024) Drug induced hypoprolactinemia. Rev Endocr Metab Disord 25:1003\u20131011. https:\/\/doi.org\/10.1007\/s11154-024-09909-6","journal-title":"Rev Endocr Metab Disord"},{"key":"1769_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11102-026-01716-3","volume":"29","author":"E Mignone","year":"2026","unstructured":"Mignone E, Saran F, Psaltis A, Jukes A, Paul R, Carroll RW et al (2026) Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey study. Pituitary 29:117. https:\/\/doi.org\/10.1007\/s11102-026-01716-3","journal-title":"Pituitary"},{"key":"1769_CR35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41574-025-01134-8","volume":"21","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Gurnell M, McCormack A, Fukuoka H, Glezer A, Langlois F et al (2025) Pituitary incidentaloma: a Pituitary Society international consensus guideline statement. Nat Rev Endocrinol 21:638\u2013655. https:\/\/doi.org\/10.1038\/s41574-025-01134-8","journal-title":"Nat Rev Endocrinol"},{"key":"1769_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s11102-026-01759-6","volume":"29","author":"F Castinetti","year":"2026","unstructured":"Castinetti F, Piazzola C, Ayuk J, Kosmin M, Losa M, Marcus HJ et al (2026) Pituitary Society Delphi consensus on the role of radiotherapy for pituitary adenomas. Pituitary 29:158. https:\/\/doi.org\/10.1007\/s11102-026-01759-6","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01769-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01769-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01769-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:15:04Z","timestamp":1792199704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01769-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01769-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This review does not report original research involving human participants, human data, or biological material.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During preparation of this manuscript, the corresponding author used ChatGPT (OpenAI; GPT-5.6 Sol; July-September 2026) to assist with language editing, organization of author-generated material, editorial refinement, and adaptation to journal format. The corresponding author critically reviewed and revised all AI-assisted output. The authors remain responsible for the accuracy, interpretation, and final content.","order":4,"name":"Ethics","label":"Use of AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article has not been published previously, posted as a preprint, or presented as a congress abstract.","order":5,"name":"Ethics","label":"Prior publication and presentation","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"167"}}